Neurosense Therapeutics Ltd Cash Flow Conversion Efficiency
Neurosense Therapeutics Ltd cash flow conversion efficiency. Based on the latest financial reports, Neurosense Therapeutics Ltd (NRSN) has a cash flow conversion efficiency ratio of 1.177x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.84 Million) by net assets ($-1.56 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Neurosense Therapeutics Ltd (2019–2025)
Cash flow conversion efficiency of Neurosense Therapeutics Ltd from 2019 to 2025. This chart illustrates how Neurosense Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Neurosense Therapeutics Ltd (NRSN) share price today for real-time trading data and today's change.
Neurosense Therapeutics Ltd Cash Flow Conversion Ratio Explained
Neurosense Therapeutics Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Neurosense Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Neurosense Therapeutics Ltd ranked by their cash flow conversion efficiency. Also see NRSN market cap for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pelikan International Corp
KLSE:5231
|
-0.039x |
|
Taiwan Thick-Film Ind
TWO:6246
|
0.120x |
|
ABERA BIOSCIENCE AB
F:8WK
|
-0.317x |
|
Inocycle Technology Tbk PT
JK:INOV
|
0.029x |
|
FIREBIRD METALS LTD
F:7Y2
|
N/A |
|
Raptis Group Ltd
AU:RPG
|
0.037x |
|
Freeport Resources Inc
V:FRI
|
-0.408x |
|
Peak Processing Limited
AU:PKP
|
0.576x |
Annual Cash Flow Conversion Efficiency for Neurosense Therapeutics Ltd (2019–2025)
The table below shows the annual cash flow conversion efficiency of Neurosense Therapeutics Ltd from 2019 to 2025. Review free cash flow generation of Neurosense Therapeutics Ltd to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-1.56 Million | $-7.67 Million | 4.917x | +225.32% |
| 2024-12-31 | $2.58 Million | $-10.13 Million | -3.924x | -182.62% |
| 2023-12-31 | $-1.76 Million | $-8.35 Million | 4.749x | +451.78% |
| 2022-12-31 | $5.62 Million | $-7.59 Million | -1.350x | -690.04% |
| 2021-12-31 | $9.01 Million | $-1.54 Million | -0.171x | +83.80% |
| 2020-12-31 | $659.00K | $-695.00K | -1.055x | -66.35% |
| 2019-12-31 | $918.00K | $-582.00K | -0.634x | -- |
About Neurosense Therapeutics Ltd
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for t… Read more